Blog | Oncotarget

Oncotarget News

microRNAs Emerge as Biomarkers and Diagnostic Tools in Soft Tissue Sarcoma

July 18, 2025

miRNAs are pivotal in regulating gene expression in STS and have been recognized as crucial biomarkers for the diagnosis, prognosis, and therapeutic decision-making in patients.”BUFFALO, NY - July 18, 2025 –... read more

Oncotarget

New Antibody Selectively Targets Immune Cells That Suppress Anti-Tumor Responses

July 16, 2025

Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME.”... read more

Oncotarget

Prostate Cancer Cells Survive Treatment by Storing Fat in Low Oxygen Conditions

July 14, 2025

manipulating LD dynamics represents a promising strategy to overcome hypoxia-induced resistance to ferroptosis and improve the success of PCa treatment.”BUFFALO, NY - July 14, 2025 – A new research paper was... read more

Oncotarget

EGFR-Targeted Therapy Resistance in Breast and Head & Neck Cancers

July 9, 2025

By synthesizing current insights on both RTK and non-RTK mediated resistance against anti-EGFR therapies, this review aims to guide future research and improve therapeutic strategies for these cancers.”BUFFALO, NY -... read more

Oncotarget

Study Identifies Key Genetic Alterations and Biomarker for Blastic Plasmacytoid Dendritic Cell Neoplasm

July 7, 2025

Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.”BUFFALO,... read more

Oncotarget

New Drug Combination Redefines First-Line Treatment for Advanced Urothelial Cancer

July 1, 2025

Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results.”BUFFALO, NY - July... read more

Oncotarget

HER2-Mutated NSCLC in Brazil Shows Diverse Genetic Patterns and Treatment Gaps

June 27, 2025

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented populations, emphasizing the need for comprehensive molecular profiling and expanded access to targeted therapies.”BUFFALO, NY -... read more

Oncotarget

WIN International Molecular Tumor Board Recommends Tailored Treatment for Advanced Colorectal Cancer

June 24, 2025

This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC.”BUFFALO, NY - June 24, 2025 – A new precision oncology paper was published... read more